Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial

Raquel González 1,2,3*, Laura García-Otero 1,3†, Clara Pons-Duran 1,2, Elena Marbán-Castro 1,2, Anna Goncé 4, Elisa Llurba 5, Maria del Mar Gif 6,7, Miguel Ángel Rodríguez-Zambrano 8, Haily Chen 1, Máximo Ramírez 1, Azucena Bardaji 1,2,3 and Clara Menendez 1,2,3

Abstract

Objectives: The primary objectives of the study are:
1. To assess the effect of hydroxychloroquine (HCQ) in reducing SARS-CoV-2 viral shedding by PCR in infected pregnant women with mild symptoms.
2. To assess the efficacy of HCQ to prevent SARS-CoV-2 infection in pregnant women in contact with an infected or suspected case.
3. To evaluate the effect of HCQ in preventing the development of the COVID-19 disease in asymptomatic SARS-CoV-2-infected pregnant women.

The secondary objectives are:
1. To determine the effect of HCQ on the clinical course and duration of the COVID-19 disease in SARS-CoV-2-infected pregnant women.
2. To determine the impact of HCQ on the risk of hospitalization and mortality of SARS-CoV-2-infected pregnant women.
3. To assess the safety and tolerability of HCQ in pregnant women.
4. To describe the clinical presentation of SARS-CoV-2 infection during pregnancy.
5. To describe the effects of maternal SARS-CoV-2 infection on pregnancy and perinatal outcomes by treatment group.

(Continued on next page)
To determine the risk of vertical transmission (intra-utero and intra-partum) of SARS-CoV-2.

**Trial design:** Randomized double-blind placebo-controlled two-arm multicentre clinical trial to evaluate the safety and efficacy of HCQ to prevent and/or minimize SARS-CoV-2 infection during pregnancy. Participants will be randomized to receive a 14-day oral treatment course of HCQ or placebo, ratio 1:1.

**Participants:** Study population: pregnant women undergoing routine prenatal follow up or attending emergency units at the participating hospitals who report either symptoms/signs suggestive of COVID-19 disease or close contact with a suspected or confirmed COVID-19 case.

**Inclusion criteria**
- Presenting with fever (≥37.5°C) and/or one mild symptom suggestive of COVID-19 disease (cough, dyspnoea, chills, odynophagia, diarrhoea, muscle pain, anosmia, dysgeusia, headache) OR being contact* of a SARS-CoV-2 confirmed or suspected case in the past 14 days
- More than 12 weeks of gestation (dated by ultrasonography)
- Agreement to deliver in the study hospitals

**Exclusion criteria**
- Known hypersensitivity to HCQ or other 4-aminoquinoline compounds
- History of retinopathy of any aetiology
- Concomitant use of digoxin, cyclosporine, cimetidine
- Known liver disease
- Clinical history of cardiac pathology including known long QT syndrome
- Unable to cooperate with the requirements of the study
- Participating in other intervention studies
- Delivery onset (characterized by painful uterine contractions and variable changes of the cervix, including some degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labours)

The study participants will be stratified by clinical presentation and SARS-CoV-2 PCR results. Assignment of participants to study groups will be as follows:

- **SARS-CoV-2-PCR confirmed, infected** pregnant women:
  a. *symptomatic* (n=100)
  b. *asymptomatic* (n=100)
- **SARS-CoV-2 PCR negative** pregnant women in contact* with a SARS-CoV-2-infected confirmed or suspected case (n=514).

*The ECDC definition of close contact will be followed.

The trial will be conducted in five hospitals in Spain: Hospital Clínic of Barcelona, Hospital Sant Joan de Déu and Hospital de la Santa Creu i Sant Pau, in Barcelona, and HM Puerta del Sur and Hospital Universitario de Torrejón, in Madrid.

**Intervention and comparator:** Participants will be randomized to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days) or placebo (2 tablets for three days, followed by one tablet for 11 days).

**Main outcomes:** The primary outcome is the number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start (one week after treatment is completed).

**Randomisation:** Allocation of participants to study arms will be done centrally by the trial’s Sponsor (the Barcelona Institute for Global Health, ISGlobal) by block randomization. This method will ensure balanced allocation to both arms. The electronic CRF will automatically assign a study number to each participant, depending on her study group and recruitment site. Each number will be related to a treatment number, which assigns them to one of the study arms.

**Blinding (masking):** Participants, caregivers, investigators and those assessing the outcomes will be blinded to group assignment. Study tablets (HCQ and placebo) will be identically packaged in small opaque bottles.
(Continued from previous page)

**Numbers to be randomised (sample size):** This study requires 200 SARS-CoV-2 infected and 514 contact pregnant women, randomised 1:1 with 100 and 227 respectively in each study arm.

**Trial Status:** Protocol version 1.0, from May 8th, 2020. Recruitment is ongoing (first patient recruited the 19th May 2020 and recruitment end anticipated by December 2020).

**Trial registration:** EudraCT number: 2020-001587-29, registered 2 April 2020. Clinicaltrials.gov identifier: NCT04410562, retrospectively registered 1 June 2020.

**Full protocol:** The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

**Keywords:** COVID-19, Randomised controlled trial, Protocol, Hydroxychloroquine, Pregnant, Women

---

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13063-020-04557-y.

**Additional file 1.** Full Study Protocol.

---

**Acknowledgements**

Llorenç Quintó, Xavier Carré, Julia del Armo, Josep Brugada, Franco Pagnoni, Mª Angeles Marcos and Luis Bernardo Herrera González for their methodological contributions.

We acknowledge Laboratorios Rubió for donating the study drugs (both hydroxychloroquine and placebo tablets).

**Authors’ contributions**

CM conceived the study and led the protocol development. RG and LG-O drafted the protocol. CPD and EMB led the development of ICF and CRFs. AG, ELL, MMG, MAZ, HC, MR and AB reviewed the protocol. All authors read and approved the final manuscript.

**Funding**

The trial is funded by the Instituto de Salud Carlos III from the Spanish Ministry of Science and Innovation extraordinary research call on SARS-COV-2 and COVID-19. Project code: COV20/286 (approved on April 17th, 2020). The funding body has no role in the design of the study, collection of data and in writing the manuscript.

**Availability of data and materials**

All data will be available to the research collaborators. Decision to publish rests solely with the researchers. The full data set will be made publicly available not later than six months after trial completion.

**Ethics approval and consent to participate**

On April 2nd, 2020, a short trial proposal was approved by the Comité de Ética en Investigación of the Hospital Clinic of Barcelona to allow the start of the clinical trial procedures in the COVID-19 emergency situation (trial code HCB/2020/0382, meeting reference 9/2020_Extraordinaria). The full trial protocol was approved as an amendment by the same committee on the ordinary meeting of May 14th, 2020. The clinical trial was authorized by the Spanish Agency of Drugs and Medical Products (AEMPS) on April 8th, 2020 (authorization tracking code FEPZWYD4D), and the agency approved the full protocol on May 22nd, 2020 (authorization tracking code FBVJZBZ766). Informed consent will be obtained from all participants.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

---

**Author details**

1ISGlobal, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain.  
2Consejo Superior de la Investigación Científica en Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.  
3Manhiça Health Research Center (CISM), Manhiça, Mozambique.  
4BCNATAL | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clinic de Barcelona, Barcelona, Spain.  
5Obstetrics and Gynecology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.  
6Obstetrics and Gynecology Department, Hospital Universitario de Torrevieja, Torrevieja de Arzobis, Madrid, Spain.  
7School of Medicine, Universidad Francisco de Vitoria, Madrid, Spain.  
8HM Puerta del Sur, Móstoles, Madrid, Spain.

Received: 23 June 2020 Accepted: 25 June 2020  
Published online: 02 July 2020

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.